Development of RNA aptamers targeting Ebola virus VP35.

Viral protein 35 (VP35), encoded by filoviruses, is a multifunctional dsRNA binding protein that plays important roles in viral replication, innate immune evasion, and pathogenesis. The multifunctional nature of these proteins also presents opportunities to develop countermeasures that target distinct functional regions. However, functional validation and the establishment of therapeutic approaches toward such multifunctional proteins, particularly for nonenzymatic targets, are often challenging. Our previous work on filoviral VP35 proteins defined conserved basic residues located within its C-terminal dsRNA binding interferon (IFN) inhibitory domain (IID) as important for VP35 mediated IFN antagonism and viral polymerase cofactor functions. In the current study, we used a combination of structural and functional data to determine regions of Ebola virus (EBOV) VP35 (eVP35) to target for aptamer selection using SELEX. Select aptamers, representing, two distinct classes, were further characterized based on their interaction properties to eVP35 IID. These results revealed that these aptamers bind to distinct regions of eVP35 IID with high affinity (10-50 nM) and specificity. These aptamers can compete with dsRNA for binding to eVP35 and disrupt the eVP35-nucleoprotein (NP) interaction. Consistent with the ability to antagonize the eVP35-NP interaction, select aptamers can inhibit the function of the EBOV polymerase complex reconstituted by the expression of select viral proteins. Taken together, our results support the identification of two aptamers that bind filoviral VP35 proteins with high affinity and specificity and have the capacity to potentially function as filoviral VP35 protein inhibitors.

[1]  W. Ian Lipkin,et al.  Discovery of an Ebolavirus-Like Filovirus in Europe , 2011, PLoS pathogens.

[2]  S. Nichol,et al.  Ebola and marburg hemorrhagic fever. , 2010, Clinics in laboratory medicine.

[3]  Z. Otwinowski,et al.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35 , 2010, Nature Structural &Molecular Biology.

[4]  S. Zaki,et al.  Inhibition of IRF-3 Activation by VP35 Is Critical for the High Level of Virulence of Ebola Virus , 2008, Journal of Virology.

[5]  H. Feldmann,et al.  Ebola and Marburg viruses: pathogenesis and development of countermeasures. , 2005, Current molecular medicine.

[6]  A. Rein,et al.  RNA Aptamers Directed to Human Immunodeficiency Virus Type 1 Gag Polyprotein Bind to the Matrix and Nucleocapsid Domains and Inhibit Virus Production , 2010, Journal of Virology.

[7]  G. Nabel,et al.  The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. , 2002, Molecular cell.

[8]  H. Feldmann,et al.  Ebola haemorrhagic fever , 2011, The Lancet.

[9]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[10]  V. Volchkov,et al.  The Ebola virus VP35 protein functions as a type I IFN antagonist. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Lawrence,et al.  RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. , 2005, RNA.

[12]  J. M. Binning,et al.  Basic Residues within the Ebolavirus VP35 Protein Are Required for Its Viral Polymerase Cofactor Function , 2010, Journal of Virology.

[13]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[14]  J. Wilson,et al.  Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. , 2001, Virology.

[15]  J. Sabina,et al.  Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. , 1999, Journal of molecular biology.

[16]  Stephan Becker,et al.  Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems , 1999, Journal of Virology.

[17]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[18]  H. Klenk,et al.  The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.

[19]  H. Feldmann,et al.  Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States. , 2002, Virus research.

[20]  N. Sullivan,et al.  Ebolavirus Proteins Suppress the Effects of Small Interfering RNA by Direct Interaction with the Mammalian RNA Interference Pathway , 2011, Journal of Virology.

[21]  Yong Wang,et al.  Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging , 2011, Analytical and bioanalytical chemistry.

[22]  P. Jahrling,et al.  Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference , 2006, The Journal of infectious diseases.

[23]  V. Volchkov,et al.  Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea Pigs , 2010, Journal of Virology.

[24]  N. Sullivan,et al.  Ebolavirus vaccines for humans and apes. , 2012, Current opinion in virology.

[25]  Yoon-Sik Lee,et al.  RNA aptamers: a review of recent trends and applications. , 2013, Advances in biochemical engineering/biotechnology.

[26]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[27]  Jens H. Kuhn,et al.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations , 2010, Archives of Virology.

[28]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[29]  D. A. Stein,et al.  Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers , 2006, PLoS pathogens.

[30]  H. Ebihara,et al.  Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. , 2013, Cell host & microbe.

[31]  S. Nichol,et al.  Reverse Genetic Generation of Recombinant Zaire Ebola Viruses Containing Disrupted IRF-3 Inhibitory Domains Results in Attenuated Virus Growth In Vitro and Higher Levels of IRF-3 Activation without Inhibiting Viral Transcription or Replication , 2006, Journal of Virology.

[32]  J. McCaskill The equilibrium partition function and base pair binding probabilities for RNA secondary structure , 1990, Biopolymers.

[33]  C. Basler,et al.  Ebolavirus VP35 is a multifunctional virulence factor. , 2010, Virulence.

[34]  M. Aman,et al.  Advances in virus-like particle vaccines for filoviruses. , 2011, The Journal of infectious diseases.

[35]  S. Nichol,et al.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. , 2004, Virology.

[36]  Virgil L. Woods,et al.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression , 2009, Proceedings of the National Academy of Sciences.

[37]  Z. Otwinowski,et al.  Structural basis for Marburg virus VP35–mediated immune evasion mechanisms , 2012, Proceedings of the National Academy of Sciences.

[38]  J. Nix,et al.  Structure of the Ebola VP35 interferon inhibitory domain , 2009, Proceedings of the National Academy of Sciences.

[39]  J. Alimonti,et al.  In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. , 2007, The Journal of infectious diseases.

[40]  Yann Ponty,et al.  VARNA: Interactive drawing and editing of the RNA secondary structure , 2009, Bioinform..

[41]  Jay Painter,et al.  Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .

[42]  Randy J. Read,et al.  Phenix - a comprehensive python-based system for macromolecular structure solution , 2012 .

[43]  C. Basler,et al.  Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. , 2010, Journal of molecular biology.

[44]  Ronny Lorenz,et al.  The Vienna RNA Websuite , 2008, Nucleic Acids Res..

[45]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[46]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[47]  G. Nabel,et al.  A Filovirus-Unique Region of Ebola Virus Nucleoprotein Confers Aberrant Migration and Mediates Its Incorporation into Virions , 2008, Journal of Virology.

[48]  B. Berkhout,et al.  The Ebola Virus VP35 Protein Is a Suppressor of RNA Silencing , 2007, PLoS pathogens.

[49]  Andrew D Ellington,et al.  Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.

[50]  A. Ellington,et al.  In Vitro Selection of RNA Aptamers to a Protein Target by Filter Immobilization , 2000, Current protocols in molecular biology.

[51]  Erica Ollmann Saphire,et al.  Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling , 2006, Journal of Virology.

[52]  T. Fitzwater,et al.  A SELEX primer. , 1996, Methods in enzymology.

[53]  M. T. McIntosh,et al.  Discovery of Swine as a Host for the Reston ebolavirus , 2009, Science.

[54]  Zongdi Feng,et al.  The VP35 Protein of Ebola Virus Inhibits the Antiviral Effect Mediated by Double-Stranded RNA-Dependent Protein Kinase PKR , 2006, Journal of Virology.

[55]  M. Bray,et al.  Filovirus research: knowledge expands to meet a growing threat. , 2007, The Journal of infectious diseases.

[56]  D. A. Stein,et al.  VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice , 2006, Antimicrobial Agents and Chemotherapy.

[57]  D. Bunka,et al.  Development of aptamer therapeutics. , 2010, Current opinion in pharmacology.

[58]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[59]  G. Peters,et al.  Phosphorylation of Specific Serine Residues in the PKR Activation Domain of PACT Is Essential for Its Ability to Mediate Apoptosis* , 2006, Journal of Biological Chemistry.

[60]  C. Basler,et al.  Ebola Virus Protein VP35 Impairs the Function of Interferon Regulatory Factor-Activating Kinases IKKε and TBK-1 , 2009, Journal of Virology.

[61]  R. N. Harty,et al.  Ebola Virus VP35-VP40 Interaction Is Sufficient for Packaging 3E-5E Minigenome RNA into Virus-Like Particles , 2006, Journal of Virology.

[62]  P. Jahrling,et al.  Towards a vaccine against Ebola virus , 2003, Expert review of vaccines.

[63]  E. Mühlberger,et al.  Ebola Virus VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory Domain , 2009, Journal of Virology.

[64]  Emiko Suzuki,et al.  Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.

[65]  Jennifer M. Binning,et al.  Aptamers in Virology: Recent Advances and Challenges , 2012, Front. Microbio..

[66]  P. Jahrling,et al.  Preliminary report: isolation of Ebola virus from monkeys imported to USA , 1990, The Lancet.